MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria‐dependent dephosphorylation of EGFR
暂无分享,去创建一个
T. Kang | Jun‐hang Luo | Jiefeng Yang | Jian-Xiong Feng | Song Gao | Bing-Sheng Yu | L. Luo | Denghui Wei | Qiuran Wang | Yihui Pan | Tiebang Kang | Tiebang Kang
[1] Z. Zeng,et al. A Positive Feedback Loop between Inactive VHL-Triggered Histone Lactylation and PDGFRβ Signaling Drives Clear Cell Renal Cell Carcinoma Progression , 2022, International journal of biological sciences.
[2] R. Deng,et al. Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis , 2021, Signal Transduction and Targeted Therapy.
[3] C. Kraft,et al. Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context , 2021, Cell metabolism.
[4] Ruihua Xu,et al. Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020 , 2021, Cancer communications.
[5] V. Margulis,et al. Deletion of Lats1/2 in adult kidney epithelia leads to renal cell carcinoma. , 2021, The Journal of clinical investigation.
[6] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[7] Alexander R. Pico,et al. WikiPathways: connecting communities , 2020, Nucleic Acids Res..
[8] Junjie Hu,et al. Mitochondrial Fusion: The Machineries In and Out. , 2020, Trends in cell biology.
[9] M. Aepfelbacher,et al. Cargo-specific recruitment in clathrin and dynamin-independent endocytosis , 2020, bioRxiv.
[10] W. Kaelin,et al. Targeting the HIF2–VEGF axis in renal cell carcinoma , 2020, Nature Medicine.
[11] Yuanzhong Wu,et al. RAB31 marks and controls an ESCRT-independent exosome pathway , 2020, Cell Research.
[12] Yi Hao,et al. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR , 2020, Oncogene.
[13] L. Sequist,et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. , 2020, The Lancet. Oncology.
[14] Huanjie Shao,et al. AIM2 promotes the development of non-small cell lung cancer by modulating mitochondrial dynamics , 2020, Oncogene.
[15] D. Chan,et al. Structural insights of human mitofusin-2 into mitochondrial fusion and CMT2A onset , 2019, Nature Communications.
[16] C. Porta,et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[17] M. Orozco,et al. Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease , 2019, Cell.
[18] Yiguo Wang,et al. PKM2 coordinates glycolysis with mitochondrial fusion and oxidative phosphorylation , 2019, Protein & Cell.
[19] Shuhan Sun,et al. Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer , 2019, Cell Death & Disease.
[20] J. Paty,et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. , 2019, The Lancet. Oncology.
[21] Christopher D. Brown,et al. Renal compartment-specific genetic variation analyses identify new pathways in chronic kidney disease , 2018, Nature Medicine.
[22] W. Rathmell,et al. Epigenetic modifiers: activities in renal cell carcinoma , 2018, Nature Reviews Urology.
[23] J. Reeves,et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.
[24] Jun‐hang Luo,et al. RIN1 promotes renal cell carcinoma malignancy by activating EGFR signaling through Rab25 , 2017, Cancer science.
[25] Charles Swanton,et al. Renal cell carcinoma , 2017, Nature Reviews Disease Primers.
[26] D. Chan,et al. Mfn1 structures reveal nucleotide-triggered dimerization critical for mitochondrial fusion , 2017, Nature.
[27] A. Mason,et al. Endosome–mitochondria interactions are modulated by iron release from transferrin , 2016, The Journal of cell biology.
[28] L. Scorrano,et al. Mitofusins, from Mitochondria to Metabolism. , 2016, Molecular cell.
[29] Umberto Capitanio,et al. Renal Cancer , 2011 .
[30] R. Montironi,et al. Metabolic alterations in renal cell carcinoma. , 2015, Cancer treatment reviews.
[31] B. Goud,et al. Integrin endosomal signalling suppresses anoikis , 2015, Nature Cell Biology.
[32] K. Hoehn,et al. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. , 2015, Molecular cell.
[33] C. Futter,et al. EGF receptor trafficking: consequences for signaling and cancer , 2014, Trends in cell biology.
[34] S. Archer. Mitochondrial dynamics--mitochondrial fission and fusion in human diseases. , 2013, The New England journal of medicine.
[35] M. Miączyńska. Effects of membrane trafficking on signaling by receptor tyrosine kinases. , 2013, Cold Spring Harbor perspectives in biology.
[36] A. Sorkin,et al. Endocytosis of receptor tyrosine kinases. , 2013, Cold Spring Harbor perspectives in biology.
[37] Na Liu,et al. Role of epidermal growth factor receptor in acute and chronic kidney injury , 2013, Kidney international.
[38] A. M. van der Bliek,et al. Mitochondrial Fission, Fusion, and Stress , 2012, Science.
[39] A. Kiger,et al. Coordination between RAB GTPase and phosphoinositide regulation and functions , 2012, Nature Reviews Molecular Cell Biology.
[40] Chunxiao Liu,et al. Rab21 attenuates EGF-mediated MAPK signaling through enhancing EGFR internalization and degradation. , 2012, Biochemical and biophysical research communications.
[41] K. Lim,et al. Mitochondrial dynamics and Parkinson's disease: focus on parkin. , 2012, Antioxidants and Redox Signaling.
[42] E. D. Robertis,et al. Endocytic control of growth factor signalling: multivesicular bodies as signalling organelles , 2011, Nature Reviews Molecular Cell Biology.
[43] M. Rao,et al. Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase , 2011, Cell.
[44] J. Tostain,et al. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. , 2010, European journal of cancer.
[45] N. Mizushima,et al. Autophagy in mammalian development and differentiation , 2010, Nature Cell Biology.
[46] C. Futter,et al. Membrane contacts between endosomes and ER provide sites for PTP1B–epidermal growth factor receptor interaction , 2010, Nature Cell Biology.
[47] Xiongwei Zhu,et al. Abnormal Mitochondrial Dynamics—A Novel Therapeutic Target for Alzheimer's Disease? , 2010, Molecular Neurobiology.
[48] P. Mischel,et al. An Unbiased Screen Identifies DEP-1 Tumor Suppressor as a Phosphatase Controlling EGFR Endocytosis , 2009, Current Biology.
[49] T. Miyake,et al. Epidermal Growth Factor Receptor Translocation to the Mitochondria , 2009, The Journal of Biological Chemistry.
[50] M. Scott,et al. Rab35 Controls Actin Bundling by Recruiting Fascin as an Effector Protein , 2009, Science.
[51] H. Stenmark. Rab GTPases as coordinators of vesicle traffic , 2009, Nature Reviews Molecular Cell Biology.
[52] A. McClatchey,et al. Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma , 2009, Proceedings of the National Academy of Sciences.
[53] W. Kaelin. The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.
[54] W. Kassouf. Editorial comment on: Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. , 2008, European urology.
[55] Frank Pétavy,et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Xuejun Jiang,et al. Mitochondrially localized EGFR is subjected to autophagic regulation and implicated in cell survival , 2008, Autophagy.
[57] Y. Yarden,et al. SnapShot: EGFR Signaling Pathway , 2007, Cell.
[58] Isabelle Robert,et al. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer , 2007, Proceedings of the National Academy of Sciences.
[59] B. Kennedy,et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis , 2007, Nature Genetics.
[60] James Brugarolas,et al. Renal-cell carcinoma--molecular pathways and therapies. , 2007, The New England journal of medicine.
[61] A. Östman,et al. DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients , 2006, Oncogene.
[62] T. Roskams,et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. , 2006, Annals of Oncology.
[63] H. Bennett,et al. A role for the small GTPase Rab21 in the early endocytic pathway , 2004, Journal of Cell Science.
[64] Masahiro Fukuoka,et al. Gefitinib — a novel targeted approach to treating cancer , 2004, Nature Reviews Cancer.
[65] Corinne Silva,et al. Phosphorylation of Y845 on the Epidermal Growth Factor Receptor Mediates Binding to the Mitochondrial Protein Cytochrome c Oxidase Subunit II , 2004, Molecular and Cellular Biology.
[66] M. Pericak-Vance,et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A , 2004, Nature Genetics.
[67] G. Meijer,et al. LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12–21 , 2003, Oncogene.
[68] G. Carpenter. The EGF receptor: a nexus for trafficking and signaling , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.
[69] S. Schmid,et al. Regulation of signal transduction by endocytosis. , 2000, Current opinion in cell biology.
[70] D. Nam,et al. Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma , 2016, Genome Biology.
[71] P. Chinnery,et al. Disturbed mitochondrial dynamics and neurodegenerative disorders , 2015, Nature Reviews Neurology.
[72] T. Pellinen,et al. Negative regulation of EGFR signalling through integrin-α1β1-mediated activation of protein tyrosine phosphatase TCPTP , 2005, Nature Cell Biology.
[73] T. Pellinen,et al. Negative regulation of EGFR signalling through integrin-alpha1beta1-mediated activation of protein tyrosine phosphatase TCPTP. , 2005, Nature cell biology.
[74] M. Karno,et al. Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.